Geron Crecimiento futuro

Future controles de criterios 5/6

Geron se prevé un crecimiento anual de los beneficios y los ingresos de 57.8% y 64.5%, respectivamente, mientras que el BPA aumentará de grow a 59.7%.

Información clave

62.1%

Tasa de crecimiento de los beneficios

62.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	20.6%
Tasa de crecimiento de los ingresos	47.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	19 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued

Dec 20

Geron: A Major Catalyst For Shareholders Arrives In January - At Last

Sep 16

Is Geron Corporation (NASDAQ:GERN) Trading At A 49% Discount?

Sep 14

Geron rises on narrower-than-expected Q2 loss

Aug 12

Rock star Growth Puts Geron (NASDAQ:GERN) In A Position To Use Debt

Aug 05

Geron: Waiting For Godot

Jul 15

Geron: TLR Is 10 Months Away

May 03

Is Geron (NASDAQ:GERN) Using Too Much Debt?

Feb 25

Geron: Just One More Year Of Patience, Then Decision Time

Feb 23

With No Catalysts At ASH, Geron Corp. Remains In A Holding Pattern

Nov 25

Is Geron (NASDAQ:GERN) Using Debt Sensibly?

Nov 04

Geron: Still A Strong Buy After New Phase II Data And 20% Return

Oct 22

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:GERN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	453	44	N/A	N/A	5
12/31/2025	251	-110	N/A	N/A	6
12/31/2024	64	-214	N/A	N/A	6
12/31/2023	0	-184	-169	-168	N/A
9/30/2023	0	-175	-163	-162	N/A
6/30/2023	0	-171	-142	-141	N/A
3/31/2023	0	-150	-141	-140	N/A
12/31/2022	1	-142	-128	-127	N/A
9/30/2022	2	-131	-115	-114	N/A
6/30/2022	1	-117	-108	-108	N/A
3/31/2022	1	-118	-97	-97	N/A
12/31/2021	1	-116	-96	-96	N/A
9/30/2021	0	-108	-86	-86	N/A
6/30/2021	0	-101	-79	-79	N/A
3/31/2021	0	-87	-73	-73	N/A
12/31/2020	0	-76	-67	-67	N/A
9/30/2020	0	-81	-65	-64	N/A
6/30/2020	0	-76	-62	-61	N/A
3/31/2020	0	-75	-58	-57	N/A
12/31/2019	0	-69	-44	-44	N/A
9/30/2019	1	-47	-37	-36	N/A
6/30/2019	1	-37	-31	-31	N/A
3/31/2019	1	-30	-26	-26	N/A
12/31/2018	1	-27	-21	-21	N/A
9/30/2018	1	-27	-22	-22	N/A
6/30/2018	1	-28	-21	-21	N/A
3/31/2018	1	-28	-21	-21	N/A
12/31/2017	1	-28	-21	-21	N/A
9/30/2017	1	-29	N/A	-17	N/A
6/30/2017	6	-26	N/A	-19	N/A
3/31/2017	6	-28	N/A	-20	N/A
12/31/2016	6	-30	N/A	-18	N/A
9/30/2016	6	-30	N/A	-23	N/A
6/30/2016	37	1	N/A	-21	N/A
3/31/2016	37	1	N/A	-22	N/A
12/31/2015	36	0	N/A	-24	N/A
9/30/2015	36	0	N/A	10	N/A
6/30/2015	1	-37	N/A	10	N/A
3/31/2015	1	-37	N/A	11	N/A
12/31/2014	1	-36	N/A	9	N/A
9/30/2014	1	-36	N/A	-26	N/A
6/30/2014	1	-35	N/A	-27	N/A
3/31/2014	1	-35	N/A	-30	N/A
12/31/2013	1	-38	N/A	-37	N/A
9/30/2013	2	-45	N/A	-40	N/A
6/30/2013	2	-53	N/A	-49	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: GERN se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.2%).

Beneficios vs. Mercado: GERN se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: GERN se espera que sea rentable en los próximos 3 años.

Ingresos vs. Mercado: GERNSe prevé que los ingresos de la empresa (64.5% al año) crezcan más deprisa que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: GERNSe prevé que los ingresos de la empresa (64.5% al año) crezcan más deprisa que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la Rentabilidad de los fondos propios de GERN se prevé elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Geron Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 7.0% to US$5.08

Consensus revenue estimates decrease by 13%

Consensus revenue estimates decrease by 21%, EPS upgraded

Forecast to breakeven in 2026

Consensus revenue estimates increase by 76%

Consensus revenue estimates fall by 14%

Recent updates

Geron Corporation, Annual General Meeting, May 09, 2024

Geron Corporation has completed a Follow-on Equity Offering in the amount of $149.999995 million.

Price target increased by 7.0% to US$5.08

Consensus revenue estimates decrease by 13%

New major risk - Share price stability

Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy

Geron Corporation Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Consensus revenue estimates decrease by 21%, EPS upgraded

Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Geron Corporation to Report Q4, 2023 Results on Feb 28, 2024

New minor risk - Share price stability

Forecast to breakeven in 2026

Geron Announces 50% Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Geron Announces Publication in the Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

Consensus revenue estimates increase by 76%

Geron Corporation has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Geron Corporation to Report Q3, 2023 Results on Nov 02, 2023

Geron Corporation Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS

Geron Corporation Announces Chief Financial Officer Changes, Effective September 25, 2023

Is Geron (NASDAQ:GERN) A Risky Investment?

Geron Corporation Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS

Consensus revenue estimates fall by 14%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Geron Corporation to Report Q2, 2023 Results on Aug 03, 2023

Geron Corporation Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS

Geron Corporation Announces Submission of New Drug Application to FDA for First-In-Class Telomerase Inhibitor Imetelstat

Geron Corporation Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS

Geron Corporation Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Consensus revenue estimates increase by 29%

Geron Corporation Announces Board Changes

Consensus revenue estimates decrease by 48%, EPS upgraded

Geron Corporation Announces Five Abstracts Related to Imetelstat Accepts at European Hematology Association Annual Meeting

Is Geron (NASDAQ:GERN) Using Debt Sensibly?

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Geron Corporation to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Chairman of the Board notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Geron Corporation has completed a Follow-on Equity Offering in the amount of $198.121928 million.

Geron Corporation has completed a Follow-on Equity Offering in the amount of $198.121928 million.

Geron Corporation Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS

Price target increased to US$4.50

An Intrinsic Calculation For Geron Corporation (NASDAQ:GERN) Suggests It's 46% Undervalued

Geron Corporation Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Geron Corporation to Report Q3, 2022 Results on Nov 03, 2022

Executive VP & COO exercised options to buy US$634k worth of stock.

Geron: A Major Catalyst For Shareholders Arrives In January - At Last

Is Geron Corporation (NASDAQ:GERN) Trading At A 49% Discount?

Geron Corporation Appoints John F. McDonald to Board of Directors

Geron Corporation Announces Update on Securities Class Action Lawsuit

Geron Corporation Announces First Patient Dosed in IMproveMF Phase 1 Combination Study in Frontline Myelofibrosis

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Geron rises on narrower-than-expected Q2 loss

Rock star Growth Puts Geron (NASDAQ:GERN) In A Position To Use Debt

Geron Corporation to Report Q2, 2022 Results on Aug 11, 2022

Geron: Waiting For Godot

Geron Corporation Announces Executive Changes

Geron Corporation Announces Board Appointment

Consensus revenue estimates increase by 14%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Geron: TLR Is 10 Months Away

Geron Corporation to Report Q1, 2022 Results on May 09, 2022

Price target increased to US$4.20